EUCTR2011-000198-29-GB进行中（未招募）不适用
A Phase 1b/2 Randomized Study of MEDI-573 in Combination with an Aromatase Inhibitor (AI) Versus AI Alone in Women with Metastatic Breast Cancer (MBC)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 178
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Histologically-confirmed MBC not deemed amenable to curative surgery or curative radiation therapy
- •Tumors are positive for ER, PgR, or both
- •Tumors must be negative for HER2 (by FISH or CISH)
- •Female gender and age = 18 years at time of study entry Postmenopausal
- •Karnofsky Performance Status = 70
- •Life expectancy of = 6 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •Subjects who received prior chemotherapy, hormonal therapy, immunotherapy or biologic therapy for advanced or metastatic disease with the following exceptions:
- •Prior adjuvant therapy with an AI or tamoxifen is allowed, provided treatment ended at least 2 weeks prior to the first dose of MEDI-573
- •Prior neoadjuvant and/or adjuvant chemotherapy for breast cancer is allowed
- •Extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor, or disease that is considered by the investigator to be rapidly progressing or life threatening (eg, subjects who are intended for chemotherapy)
- •Active brain metastases with the exception of subject has been treated and are asymptomatic and there has been no evidence of CNS progression for at least 4 weeks of first dose of MEDI-573 Evidence of ongoing spinal cord compression or leptomeningeal carcinomatosis
- •Unresolved toxicities from prior therapy with the exception of alopecia that have not resolved to = Grade 1 at the time of starting study treatment
- •Previous treatment with agents that target the IGF receptor History of allergy or reaction attributed to compounds of chemical or biologic composition similar to those of MEDI-573 or AI
- •History of another invasive malignancy within 5 years except for curatively resected nonmelanoma skin cancer or carcinoma in situ of the cervix
- •Poorly controlled diabetes mellitus
研究者
相似试验
进行中（未招募）
1 期
A study in women with advanced breast cancer treated with standard therapy with or without MEDI-573Advanced Metastatic Breast Cancer (MBC)MedDRA version: 18.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000198-29-DEMedImmune, LLC178
进行中（未招募）
1 期
A study in women with advanced breast cancer treated with standard therapy with or without MEDI-573Advanced Metastatic Breast Cancer (MBC)MedDRA version: 20.0 Level: PT Classification code 10057654 Term: Breast cancer female System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10006202 Term: Breast cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1 Level: PT Classification code 10055113 Term: Breast cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000198-29-BEMedImmune, LLC178
进行中（未招募）
1 期
A study in women with advanced breast cancer treated with standard therapy with or without MEDI-573EUCTR2011-000198-29-ESMedImmune, LLC267
进行中（未招募）
1 期
A study in women with advanced breast cancer treated with standard therapy with or without MEDI-573EUCTR2011-000198-29-HUMedImmune, LLC178
进行中（未招募）
不适用
Treatment of Adults with Advanced, Untreated, Non-Small Cell Lung Cancer With Either MEDI-575 or MEDI-575 Plus Carboplatin and PaclitaxelPreviously untreated advanced non-small cell lung cancer in adultsMedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023854-35-HUMedImmune, LLC112